CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
A good retirement savings plan helps you accumulate wealth for the future. Discover strategies to maximize your savings for retirement.
20,039 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
As housing markets tighten, brokerages race to deploy must-have real estate marketing tools in 2026. This story break...
Applied Digital signals a slower AI data-center buildout through 2027 amid labor constraints, with hyperscalers pushi...
Governor Newsom signs a balanced budget, delivering a zero-deficit forecast for two years while locking in $1.7 billi...
Biotech investing often rides on data, not on dreams. This educational piece uses a fictional company to show how wal...
Meta faced a pivotal near-miss in 2026 as it stepped back from a Kalshi deal. The decision highlights how regulatory ...
A major reinsurance renewal helped Lemonade rewrite its profit picture, sending LMND higher in a short week. Here’s w...
What would Steve Jobs Do in today’s markets for investors? A fresh, original look at leadership, product focus, and t...
As spacex insider lockups start, investors watch for how staged unlocks could affect liquidity and volatility. This a...
Oregon regulators approve POWER Act pricing that shifts costs from households to energy-intensive users. Data centers...
As the four biggest U.S. carriers command about three-quarters of capacity, travelers face fewer options on many rout...
This week brought a burst of excitement around Criteo as takeover chatter swirled and the stock jumped. We break down...